EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Novogene Co. Ltd. (688315) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Novogene Co. Ltd. ¥7.25, price ¥19.39, upside -62.6%, quality 56 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · CN · ISIN CNE1000052X3

NC Broad data Sep 23, 2026

Novogene Co. Ltd.

688315 · SHG

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value ¥7.25 · Strongly overvalued (−63%)
!Quality 56/100
✓Healthy Growth (revenue 5y +8.2 %/yr)
!Thin margins · 7.2% net margin (TTM)
✓generates free cash flow
·0.23% dividend yield
!Mixed vs. peers (7/13)
!Narrow moat 39/100
!Weak on past: 25 out of 100
!Weak on dividend: 5 out of 100
Watch Novogene Co. Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥67.54 ¥9.05 Fair Value ¥7.25 Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range ¥9.05 – ¥67.54 · fair‑value band ¥5.07 – ¥9.52 · the ¥19.39 price screens above the ¥7.25 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Novogene Co. in your weekly email

Every Wednesday you see whether Novogene Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Novogene Co., Ltd., together with its subsidiaries, provides genomic services and solutions in Mainland China, Hong Kong, Macau, Taiwan, and internationally.

Show more

Novogene Co., Ltd., together with its subsidiaries, provides genomic services and solutions in Mainland China, Hong Kong, Macau, Taiwan, and internationally. The company offers genomic solutions comprising human, animal, plant, and microbial whole genome sequencing, as well as human and mouse whole exome sequencing, microbial de novo sequencing, animal and plant de novo sequencing, and 16S/18S/ITS amplicon and shotgun metagenomic sequencing; transcriptomics solutions, such as mRNA, long non-coding RNA, small RNA, circular RNA, whole transcriptome, isoform, direct RNA, prokaryotic RNA, and meta transcriptome sequencing; and single cell gene expression, single cell long road read transcriptome, and visium formalin-fixed paraffin-embedded spatial transcriptome solutions. It also provides epigenomic solutions comprising whole genome bisulfite, reduced representation bisulfite, chromatin immunoprecipitation, and RNA immunoprecipitation sequencing; premade library and proteomics services; clinical diagnostics services, such as clinical whole exome sequencing and clinical panels; biopharma services consisting of discovery and pre-clinical, translational and clinical, and companion diagnostics; and support services. In addition, the company offers sequencing platforms under the ILLUMINA, PACBIO, 10X GENOMICS, and NANOPORE brands; and basic scientific research services in life sciences, and medical research and technical services. Its services are used in cancer research, immuno-oncology agrigenomics, environment, food science, human microbiome, plant and animal microbiome, drug discovery and development, and rare and complex diseases applications. The company serves research universities, research institutes, hospitals, pharmaceutical research and development companies, and agricultural companies. Novogene Co., Ltd. was founded in 2011 and is headquartered in Beijing, China.

Stock analysis

Novogene Co. Ltd. (688315) currently trades at ¥19.39, while our model-based Fair Value estimate is ¥7.25, implying the stock looks roughly 167.5% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of ¥9.01 per share, and 0 of the 26 models we run sit above the ¥19.39 price.

Bear case: the Dividend Discount group reads lowest at ¥0.7400, and 26 of the 26 models stay below the price. Evidence for this calculation is high.

Scenario range: ¥5.07 (bear) to ¥9.52 (bull), the price of ¥19.39 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Novogene Co. Ltd. reported revenue of 2.2B CNY in FY2025 versus 1.9B CNY in FY2021, a compound +4.3%/yr. Reported net income was 166M CNY in FY2025, compounding −7.3%/yr from FY2021.

Key figures

Market cap 7.9B CNY (≈ $1.2B) · P/E ratio 48.5 · P/S ratio 3.64 · EPS (TTM) ¥0.4000 · Dividend yield 0.2% · Net margin 7.5% · Return on equity 6.4% · Return on assets (EBIT) 6.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 62% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −63%, 688315 screens richer than that median.

Fair Value models

Bear ¥5.07 Fair Value ¥7.25 Bull ¥9.52
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.2597 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF ¥4.41 ¥6.67 ¥10.33 78
Residual Income ¥4.96 ¥5.09 ¥5.12 76
Growth DCF ¥4.39 ¥6.50 ¥9.79 75
All 26 models by family
DCF Models
FCF DCF ¥4.41 ¥6.67 ¥10.33 78
Owner Earnings ¥7.20 ¥11.41 ¥18.22 72
5Y Revenue Exit ¥4.99 ¥7.91 ¥11.85 69
5Y EBITDA Exit ¥7.45 ¥12.87 ¥19.61 71
5Y P/E Exit ¥6.22 ¥10.39 ¥15.08 67
10Y Revenue Exit ¥4.61 ¥7.26 ¥11.23 63
10Y EBITDA Exit ¥6.33 ¥10.76 ¥17.42 64
10Y P/E Exit ¥5.53 ¥9.01 ¥13.80 61
Earnings-Based
Graham-Dodd ¥2.71 ¥11.47 ¥15.65 64
Lynch FV ¥2.92 ¥4.17 ¥5.42 61
PEG = 1.0 ¥2.92 ¥4.17 ¥5.42 57
EPV ¥4.93 ¥5.52 ¥6.04 70
Dividend Discount
Gordon GGM ¥0.4300 ¥0.8500 ¥1.29 67
DDM Multi-Stage ¥0.4300 ¥0.7400 ¥0.9000 67
Multiples
P/E Multiple ¥6.59 ¥8.78 ¥10.98 63
P/S Multiple ¥5.09 ¥6.78 ¥8.48 58
P/B Multiple ¥5.09 ¥6.78 ¥8.48 55
EV/EBIT ¥7.09 ¥9.06 ¥11.04 63
EV/EBITDA ¥9.80 ¥12.68 ¥15.56 64
EV/Revenue ¥5.39 ¥7.20 ¥9.01 52
Asset-Based
NCAV (Graham) ¥3.19 ¥4.27 ¥6.37 51
Growth DCF
Growth DCF ¥4.39 ¥6.50 ¥9.79 75
Rev-Margin DCF ¥4.99 ¥7.84 ¥11.41 69
Economic Profit
Residual Income ¥4.96 ¥5.09 ¥5.12 76
ROIC Compounder ¥4.93 ¥5.52 ¥6.04 70
Growth Earnings
Growth-Adj P/E ¥5.07 ¥7.25 ¥9.42 67

Open the full fair value analysis →

Notify me when 688315 reaches fair value

Put 688315 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 56/100

Of which business quality 57 · Market factors (momentum, volatility) 70

Profitability 38
Margins and returns on capital today
Quality Growth 30
Are margins and returns improving?
Cashflow 40
Earnings quality: real cash, not paper profit
Fin. Strength 88
Balance sheet, leverage, solvency risk
Investment 63
Disciplined investing over empire-building
Low Volatility 54
Calm price path (market factor)
Momentum 75
Price trend over the last 3–12 months (market factor)
52W Momentum 78
Distance to the 52-week high (market factor)
Net Issuance 87
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 71/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+4.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
Start year 2020 (pandemic). Over 10 years: +21.7% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.7%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+5.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.1%
Dividend (yield on the price)0.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5% vs −10%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 9%
Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+28.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +26.2% a year for the price.

688315 screens 167% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Novogene Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks

Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 56 · Above median
Fair Value upside −63% · Below median
Profitability
Return on equity (TTM) 6% · Top 25%
Return on assets 3% · Top 25%
Net margin (TTM) 7% · Above median
Operating margin (TTM) 7% · Above median
Growth and dividend
Revenue growth 11% · Above median
Dividend yield (TTM) 0.2% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 48.5× · Pricier than median
P/B 2.96× · Pricier than median
P/S (TTM) 3.47× · Cheaper than median
P/FCF 10.4× · Pricier than median
EV/EBITDA 27.0× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)54 · sector 0
PAST (return on equity)25 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)5 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.99 $566.49 +10%
Regeneron Pharmaceuticals, Inc REGN $803.90 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.24 A$197.16 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BeOne Medicines AG ONC $368.08 $280.94 −24%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Novogene Co. Ltd. · Fair Value
¥7.25 −167%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Novogene Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/688315

Frequently asked questions

Is Novogene Co. Ltd. (688315) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of ¥7.25 versus a price of ¥19.39, about −63% upside (overvalued).
What is the fair value of 688315?
Our model-based fair value for Novogene Co. Ltd. is ¥7.25 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥19.39.
What is the quality score of 688315?
Novogene Co. Ltd. has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Novogene Co. Ltd. (688315)?
Our model-based price target is the fair value of ¥7.25 (as of Sep 23, 2026) from 26 valuation models. Cautious scenario ¥5.07, optimistic scenario ¥9.52. It is a calculation from audited fundamentals, not an analyst target.
What is the Novogene Co. Ltd. stock forecast for 2026?
Our models put fair value at ¥7.25, about −63% upside versus a price of ¥19.39 (overvalued). Cautious scenario ¥5.07, optimistic scenario ¥9.52. The calculation is refreshed regularly with new filings.
What is the revenue of Novogene Co. Ltd. (688315)?
Novogene Co. Ltd. reported trailing-twelve-month revenue of about 2.3B CNY (latest available figure, as of Sep 23, 2026).
Does Novogene Co. Ltd. pay a dividend?
Novogene Co. Ltd. currently shows a dividend yield of about 0.23% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Novogene Co. Ltd. (688315)?
For today's price to be fair in a discounted-cash-flow model, Novogene Co. Ltd. would have to grow free cash flow by +28.3 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.2 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of 688315 use?
Our models discount Novogene Co. Ltd. at 9.5 %: a base by market capitalisation (mid), damped by beta 0.66, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Novogene Co. Ltd. that is +28.3 % per year a year over ten years, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has Novogene Co. Ltd. (688315) delivered so far?
Over the past 5 years revenue at Novogene Co. Ltd. grew +8.2 % a year. The price currently implies +28.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Novogene Co. Ltd. (688315) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Novogene Co. Ltd. (+28.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Novogene Co. Ltd. (688315)?
The free-cash-flow yield on the price is 1.43 %: that much free cash flow Novogene Co. Ltd. produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Novogene Co. Ltd. (688315)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Novogene Co. Ltd. it is ¥7.25 per share (as of Sep 23, 2026), against a price of ¥19.39. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Novogene Co. Ltd. stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 688315 trades above its calculated fair value: price ¥19.39, fair value ¥7.25, a gap of about −63% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688315?
No. The price is what the market pays today (¥19.39); the fair value is what the company's own numbers justify (¥7.25). For Novogene Co. Ltd. the two are ¥12.14 per share apart. That gap is exactly why we show both numbers side by side.
How much is Novogene Co. Ltd. worth?
The market values Novogene Co. Ltd. at about 7.9B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥19.39; our models calculate a fair value of ¥7.25 per share.
What do the bullish and bearish scenarios say about 688315?
Our models span a range for Novogene Co. Ltd.: cautious scenario ¥5.07, base ¥7.25, optimistic ¥9.52 per share (as of Sep 23, 2026, price ¥19.39). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688315?
Novogene Co. Ltd. trades at a price-to-earnings ratio of 48.5 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥7.25 is built from several models across several years. Other multiples: P/B 3.0, P/S 3.5, EV/EBITDA 27.0.
How solid is the balance sheet of Novogene Co. Ltd. (688315)?
Balance-sheet figures for Novogene Co. Ltd. (as of Sep 23, 2026): return on equity 6.4%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 688315 from its 52-week high?
Novogene Co. Ltd. trades at ¥19.39, at its 52-week high of ¥19.39 and 62% above the low of ¥11.94 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of ¥7.25 is for.
Which stocks are comparable to Novogene Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Novogene Co. Ltd. stock attractive at the current price?
The data as of Sep 23, 2026: price ¥19.39, calculated fair value ¥7.25 (−63%), Quality Score 56/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688315 calculated?
We run Novogene Co. Ltd. through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥7.25, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Novogene Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Novogene Co. Ltd. (688315)?
The closing price on Sep 23, 2026 was ¥19.39. Our model-based fair value is ¥7.25, about −63% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Novogene Co. Ltd. right now?
The price sits above even our optimistic bull case (¥9.52). The favourable scenario is already priced in. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥5.07 to ¥9.52) leaves room in how you read the outcome.

Key figures of Novogene Co. Ltd.

How large is the market capitalisation of Novogene Co. Ltd. (688315)?
The market capitalisation of Novogene Co. Ltd. is 7.9B CNY (≈ $1.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Novogene Co. Ltd. (688315)?
The price-to-sales ratio of Novogene Co. Ltd. is 3.64 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Novogene Co. Ltd. (688315)?
Earnings per share at Novogene Co. Ltd. are ¥0.4000 (price ÷ EPS = P/E 48.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Novogene Co. Ltd. (688315)?
The dividend yield of Novogene Co. Ltd. is 0.2% (payout 11.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Novogene Co. Ltd. (688315)?
The net margin of Novogene Co. Ltd. is 7.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Novogene Co. Ltd. (688315)?
The return on equity (ROE) of Novogene Co. Ltd. is 6.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Novogene Co. Ltd. (688315)?
On an EBIT basis the return on assets of Novogene Co. Ltd. is 6.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Novogene Co. Ltd. (688315)?
The operating margin of Novogene Co. Ltd. is 6.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Novogene Co. Ltd. (688315)?
Revenue at Novogene Co. Ltd. is growing +10.8% versus a year earlier (3y avg +4.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Novogene Co. Ltd. (688315)?
Earnings per share at Novogene Co. Ltd. are growing −12.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Novogene Co. Ltd. (688315) hold?
Novogene Co. Ltd. holds more cash than debt, 374M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Novogene Co. Ltd. in the live analysis

One click puts Novogene Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.